氢多拉司琼 | 127951-99-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 氢多拉司琼
• 英文名称: trans-hexahydro-8-(3-indolylcarbonyloxy)-2,6-methano-2H-quinolizin-3(4H)-ol
• 英文别名: endo-8-(3-Indolylcarbonyloxy)octahydro-2,6-methano-2H-quinolizin-3-ol；Hydrodolasetron；(10-hydroxy-8-azatricyclo[5.3.1.03,8]undecan-5-yl) 1H-indole-3-carboxylate
• CAS: 127951-99-9
• 化学式: C₁₉H₂₂N₂O₃
• 分子量: 326.395
• InChiKey: MLWGAEVSWJXOQJ-UHFFFAOYSA-N

物化性质

• 沸点：
  534.7±50.0 °C(Predicted)
• 密度：
  1.37±0.1 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  65.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of cardiac arrhythmia
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0330788A1

  公开（公告）日：1989-09-06

  The present invention is directed to the use of heterocyclic esters of hexahydro-8-hydroxy-2,6-methano-2H-­quinolizin-3(4H)-ones and hexahydro-B-hydroxy-2,6-methano-­2H-quinolizines in the manufacture of cardiac antiarrhythmic agents

  本发明涉及在制造心脏抗心律失常药物中使用六氢-8-羟基-2,6-甲基-2H-喹诺利啉-3(4H)-酮和六氢-B-羟基-2,6-甲基-2H-喹诺利啉的杂环酯。
• Use of quinolizinone and quinolizine derivatives in the manufacture of medicaments for the treatment of glaucoma
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0329903A1

  公开（公告）日：1989-08-30

  The present invention is directed to the use of esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-­ones and hexahydro-8-hydroxy-2,6-methano-2H-quinolizines in the manufacture of ocular hypotensive agents.

  本发明涉及六氢-8-羟基-2,6-甲桥-2H-喹嗪-3(4H)-酮和六氢-8-羟基-2,6-甲桥-2H-喹嗪的酯类在制造降眼压剂中的应用。
• Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of anxiety
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0329904A1

  公开（公告）日：1989-08-30

  The present invention is directed to the use of esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-­ones and hexahydro-8-hydroxy-2,6-methano-2H-quinolizines in the manufacture of anxiolytic agents.

  本发明涉及六氢-8-羟基-2,6-甲桥-2H-喹嗪-3(4H)-酮和六氢-8-羟基-2,6-甲桥-2H-喹嗪的酯类在抗焦虑剂生产中的应用。
• Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of cardiac arrhythmias
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0330824A1

  公开（公告）日：1989-09-06

  The present invention is directed to the use of hetrocyclic esters of hexahydro-8-hydroxy-2,6-methano-2H-­quinolizin-3(4H)-one and hexahydro-8-hydroxy-2,6-methano-2H-­quinolizines as cardiac antiarrhythmic agents.

  本发明是关于六氢-8-羟基-2,6-甲桥-2H-喹嗪-3(4H)-酮和六氢-8-羟基-2,6-甲桥-2H-喹嗪的六环酯作为抗心律失常药物的用途。
• Use of quinolizinone and quinolizine derivatives in the manufacture of medicaments for the treatment of psychosis
  申请人：MERRELL DOW PHARMACEUTICALS INC.

  公开号：EP0329902A1

  公开（公告）日：1989-08-30

  The present invention is related to the use of esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3(4H)-­ones, and hexahydro-8-hydroxy-2,6-methano-2H-quinolizines in the manufacture of a medicament for the treatment of psychosis.

  本发明涉及六氢-8-羟基-2,6-甲桥-2H-喹嗪-3(4H)-酮和六氢-8-羟基-2,6-甲桥-2H-喹嗪的酯类在制造治疗精神病药物中的应用。